<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1820">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393727</url>
  </required_header>
  <id_info>
    <org_study_id>TSUNAMI</org_study_id>
    <nct_id>NCT04393727</nct_id>
  </id_info>
  <brief_title>Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19</brief_title>
  <acronym>TSUNAMI</acronym>
  <official_title>Transfusion of Convalescent Plasma for the Early Treatment of pneumonIa Due to SARSCoV2: a Multicenter Open Label Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliero, Universitaria Pisana</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      No specific therapeutic agents or vaccines for COVID-19 are available. Several therapies, are
      under investigation, but the antiviral efficacy of these drugs is not yet known. The use of
      convalescent plasma was recommended as an empirical treatment during outbreaks of Ebola virus
      in 2014, and a protocol for treatment of Middle East respiratory syndrome coronavirus with
      convalescent plasma was established in 2015. Accordingly, we hypothesized that use of
      convalescent plasma transfusion could be beneficial in patients infected with SARS-CoV-2.

      This is a multicenter prospective randomized clinical trial to evaluate safety and efficacy
      of early use of convalescent plasma in patients with SARS-CoV2 pneumonia.

      Primary endpoint will be the efficacy, evaluated as the need of invasive mechanical
      ventilation defined by PaO2/FiO2 ratio &lt;150.

      Secondary endpoints will be: mortality rates, time to invasive mechanical ventilation, time
      to virological cure, length of hospital stay, toxicity.

      Patients with SARS-CoV2 pneumonia not requiring mechanical ventilation (both non invasive and
      invasive) will be randomized 1:1 to receive or not convalescent plasma. Patients in the
      plasma group will receive 200 ml of convalescent plasma, continuing already administered
      standard therapy, while patients in the control group will continue to receive the standard
      therapy. A rescue therapy will be allowed in case of clinical worsening.

      Patients will be followed-up until 30 days from randomization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter prospective randomized open-label clinical trials. Patients with
      pneumonia due to SARS-CoV-2 will be included and randomized to receive or not convalescent
      plasma.

      Convalescent plasma will be collected by cured patients with previous diagnosis of COVID-19.
      More specifically, inclusion and exclusion criteria for donors will be the following.

      Inclusion criteria for donors:

        -  age &gt; 18 and &lt;60 years

        -  confirmed diagnosis of COVID-19: PCR on nasopharynx swab or positive IgG

        -  presence of 2 negative nasopharynx swabs for patients with previous positive swab and
           presence of 1 negative nasopharynx swab for patients with positive IgG

      Exclusion criteria for donors:

        -  age &lt; 18 ys or &gt;60 ys

        -  other conditions that controindicate blood donation

      Collected plasma will undergo all procedures for blood preparation. Plasma will be tested
      with enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody titers.

      Patients eligible for the study will be selected among hospitalized patients with SARS-CoV2
      pneumonia. More specifically, the following criteria will used for inclusion in the study.

      Inclusion criteria for recipients:

        -  age &gt;18 ys

        -  confirmed diagnosis of SARS-CoV2 pneumonia

        -  PaO2/FiO2 200-350

      Exclusion criteria for recipients:

        -  PaO2/FiO2 &lt;200

        -  need of non invasive or invasive mechanical ventilation

      Patients will be randomized 1:1 to receive or not convalescent plasma. All patients will be
      followed-up for 30 days after randomization.

      Primary endpoint will be the need of mechanical ventilation, defined as PaO2/FiO2 &lt;150.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need of invasive mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Need of invasive mechanical ventilation defined as PaO2/FiO2 &lt;150</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rates</measure>
    <time_frame>30 days</time_frame>
    <description>Thirty-day mortality rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to invasive mechanical ventilation</measure>
    <time_frame>30 days</time_frame>
    <description>Days from randomization to invasive mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virologic cure</measure>
    <time_frame>30 days</time_frame>
    <description>Days from randomization to virologic cure defined as 2 consecutive negative nasopharynx swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>Days from randomization to discharge or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Occurrence of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>COVID</condition>
  <condition>SARS-CoV 2</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the intervention group will receive 200 cc of convalescent plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will continue to receive standard therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CONVALESCENT PLASMA</intervention_name>
    <description>Convalescent plasma will be collected by healthy donors, cured by COVID-19 and, after standard preparation and dosage of neutralizing antibodies, will be administered to patients with SARS-CoV2 pneumonia</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any gender

          -  Age &gt; 18 years on day of signing informed consent

          -  Informed written consent for participation in the study

          -  Virological diagnosis of SARS-CoV-2 infection (real-time PCR)

          -  Hospitalized due to clinical instrumental diagnosis of pneumonia

          -  PaO2/FiO2 ratio 200-350

        Exclusion Criteria:

          -  mechanical ventilation (both invasive and non-invasive)

          -  PaO2/FiO2&lt;200

          -  known hypersensitivity to immunoglobulin or blood components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Menichetti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliero, Universitaria Pisana</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Falcone</last_name>
    <phone>050996735</phone>
    <email>marco.falcone@unipi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Falcone</last_name>
      <email>marco.falcone@unipi.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Menichetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Falcone</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 16, 2020</study_first_submitted>
  <study_first_submitted_qc>May 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliero, Universitaria Pisana</investigator_affiliation>
    <investigator_full_name>Francesco Menichetti</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>covid-19</keyword>
  <keyword>SARS-CoV2</keyword>
  <keyword>pneumonia</keyword>
  <keyword>convalescent plasma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

